Table 3.

Multivariate Analysis for Risk of ALL Relapse

Patient Characteristics	P Valuea	Hazard Ratiob (95% CI)
MRD Positive	<×10−6	3.73 (2.98, 4.68)
Leukocyte count at diagnosis (≥50,000/ul)	6.00×10−6	1.93 (1.45, 2.57)
DNA Index (≥1.16)	2.58×10−4	0.59 (0.45, 0.79)
Native American ancestry	0.017	1.84 (1.12, 3.04)
Age at diagnosis (≥10 years)	0.010	1.39 (1.08, 1.78)
ETV6-RUNX1 c	0.012	0.67 (0.49, 0.91)
T-cell lineagec	0.146	0.67 (0.40, 1.15)
BCR-ABL c	0.454	1.48 (0.53, 4.12)
TCF3-PBX1 c	0.793	0.93 (0.53, 1.63)
MLL rearrangementsc	0.935	0.96 (0.41, 2.25)

Abbreviations: MRD: minimal residual disease; CI: confidence interval

^aAssociations with risk of relapse (any relapse) were assessed using the Fine and Gray’s regression model.

^bHazard ratio: the relative difference (increase or decrease) in risk of ALL relapse when the patient is positive for the clinical feature of interest (e.g., 1.84-fold increase in relapse risk for every 100% increase in NA ancestry).

^cTerms refer to cancer characteristics of the ALL cells that may have prognostic significance and are used to subdivide cases. All prognostic features are dichotomized for presence vs absence of the patient characteristic except for NA ancestry, which is treated as a continuous variable. Supplementary Table S2 includes identical multivariate analyses with dichotomized variables used for all variables, including ancestry.